The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Soluble Interleukin-15 Receptor α (IL-15Rα)-sushi as a Selective and Potent Agonist of IL-15 Action through IL-15Rβ/γ
Open accessAbstract
Interleukin-15 (IL-15) is crucial for the generation of multiple lymphocyte subsets (natural killer (NK), NK-T cells, and memory CD8 T cells), and transpresentation of IL-15 by monocytes and dendritic cells has been suggested to be the dominant activating process of these lymphocytes. We have previously shown that a natural soluble form of IL-15R alpha chain corresponding to the entire extracellular domain of IL-15R alpha behaves as a high affinity IL-15 antagonist. In sharp contrast with this finding, we demonstrate in this report that a recombinant, soluble sushi domain of IL-15R alpha, which bears most of the binding affinity for IL-15, behaves as a potent IL-15 agonist by enhancing its binding and biological effects (proliferation and protection from apoptosis) through the IL-15R beta/gamma heterodimer, whereas it does not affect IL-15 binding and function of the tripartite IL-15R alpha/beta/gamma membrane receptor. Our results suggest that, if naturally produced, such soluble sushi domains might be involved in the IL-15 transpresentation mechanism. Fusion proteins (RLI and ILR), in which IL-15 and IL-15R alpha-sushi are attached by a flexible linker, are even more potent than the combination of IL-15 plus sIL-15R alpha-sushi. After binding to IL-15R beta/gamma, RLI is internalized and induces a biological response very similar to the IL-15 high affinity response. Such hyper-IL-15 fusion proteins appear to constitute potent adjuvants for the expansion of lymphocyte subsets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Mast Cells Express Novel Functional IL-15 Receptor α Isoforms
Bulanova, E., Budagian, V., Orinska, Z., Krause, H., Paus, R., & Bulfone‐Paus, S. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.10.5045 · Cited by 45
RetractedReversible Defects in Natural Killer and Memory Cd8 T Cell Lineages in Interleukin 15–Deficient Mice
Kennedy, M. K., Glaccum, M., Brown, S. N., Butz, E. A., Viney, J. L., Embers, M., Matsuki, N., Charrier, K., Sedger, L., Willis, C. R., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.5.771 · Cited by 1,634
Cloning of a T Cell Growth Factor that Interacts with the β Chain of the Interleukin-2 Receptor
Grabstein, K. H., Eisenman, J., Shanebeck, K., Rauch, C., Srinivasan, S., Fung, V., Beers, C., Richardson, J., Schoenborn, M. A., Ahdieh, M., et al. (1994) · Science · doi:10.1126/science.8178155 · Cited by 1,422
Carson, W. E., Giri, J. G., Lindemann, M. J., Linett, M. L., Ahdieh, M., Paxton, R., Anderson, D., Eisenmann, J., Grabstein, K., & Caligiuri, M. A. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.4.1395 · Cited by 1,092
Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15.
Giri, J. G., Ahdieh, M., Eisenman, J., Shanebeck, K., Grabstein, K., Kumaki, S., Namen, A., Park, L. S., Cosman, D., & Anderson, D. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06576.x · Cited by 981
IL-15Rα Recycles and Presents IL-15 In trans to Neighboring Cells
Dubois, S., Mariner, J., Waldmann, T. A., & Tagaya, Y. (2002) · Immunity · doi:10.1016/s1074-7613(02)00429-6 · Cited by 913
Control of Homeostasis of CD8 + Memory T Cells by Opposing Cytokines
Ku, C. C., Murakami, M., Sakamoto, A., Kappler, J., & Marrack, P. (2000) · Science · doi:10.1126/science.288.5466.675 · Cited by 816
Soluble receptors for cytokines and growth factors: generation and biological function
Rose-John, S., & Heinrich, P. C. (1994) · Biochemical Journal · doi:10.1042/bj3000281 · Cited by 775
A bioactive designer cytokine for human hematopoietic progenitor cell expansion
Fischer, M., Goldschmitt, J., Peschel, C., Brakenhoff, J. P. G., Kallen, K.-J., Wollmer, A., Grötzinger, J., & Rose-John, S. (1997) · Nature Biotechnology · doi:10.1038/nbt0297-142 · Cited by 530
Self-citationIL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice
Marks-Konczalik, J., Dubois, S., Losi, J. M., Sabzevari, H., Yamada, N., Feigenbaum, L., Waldmann, T. A., & Tagaya, Y. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.200363097 · Cited by 433
Cited by
Cytokines in clinical cancer immunotherapy
Berraondo, P., Sanmamed, M. F., Ochoa, M. C., Etxeberria, I., Aznar, M. A., Pérez-Gracia, J. L., Rodríguez-Ruiz, M. E., Ponz-Sarvise, M., Castañón, E., & Melero, I. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0328-y · Cited by 1,205
Effector and Memory CTL Differentiation
Williams, M. A., & Bevan, M. J. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.25.022106.141548 · Cited by 949
IL-15 trans-presentation promotes human NK cell development and differentiation in vivo
Huntington, N. D., Legrand, N., Alves, N. L., Jaron, B., Weijer, K., Plet, A., Corcuff, E., Mortier, E., Jacques, Y., Spits, H., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082013 · Cited by 577
Self-citationNK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy
Wang, W. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00368 · Cited by 567
Cytokines in the Treatment of Cancer
Conlon, K. C., Miljkovic, M. D., & Waldmann, T. A. (2019) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2018.0019 · Cited by 518
Cytokines in Cancer Immunotherapy
Waldmann, T. A. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028472 · Cited by 507
Survey of the year 2003 commercial optical biosensor literature
Rich, R. L., & Myszka, D. G. (2005) · Journal of Molecular Recognition · doi:10.1002/jmr.726 · Cited by 505
Mammalian cell protein expression for biopharmaceutical production
Zhu, J. (2012) · Biotechnology Advances · doi:10.1016/j.biotechadv.2011.08.022 · Cited by 491
Hurton, L. V., Singh, H., Najjar, A. M., Switzer, K. C., Mi, T., Maiti, S., Olivares, S., Rabinovich, B., Huls, H., Forget, M.-A., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1610544113 · Cited by 461
Targeting cytokine and chemokine signaling pathways for cancer therapy
Yi, M., Li, T., Niu, M., Zhang, H., Wu, Y., Wu, K., & Dai, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01868-3 · Cited by 455
Natural killer cell trafficking in vivo requires a dedicated sphingosine 1-phosphate receptor
Walzer, T., Chiossone, L., Chaix, J., Calver, A., Carozzo, C., Garrigue-Antar, L., Jacques, Y., Baratin, M., Tomasello, E., & Vivier, E. (2007) · Nature Immunology · doi:10.1038/ni1523 · Cited by 431
Self-citationConverting IL-15 to a superagonist by binding to soluble IL-15Rα
Rubinstein, M. P., Kovar, M., Purton, J. F., Cho, J.-H., Boyman, O., Surh, C. D., & Sprent, J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600240103 · Cited by 416
IL-15/IL-15 receptor biology: A guided tour through an expanding universe
BUDAGIAN, V, BULANOVA, E., PAUS, R., & BULFONEPAUS, S. (2006) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2006.05.001 · Cited by 385
Combined IL-15/IL-15Rα Immunotherapy Maximizes IL-15 Activity In Vivo
Stoklasek, T. A., Schluns, K. S., & Lefrançois, L. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.9.6072 · Cited by 366
Lutz, C. T., & Quinn, L. S. (2012) · Aging · doi:10.18632/aging.100482 · Cited by 333
Memory T cells: strategies for optimizing tumor immunotherapy
Liu, Q., Sun, Z., & Chen, L. (2020) · Protein & Cell · doi:10.1007/s13238-020-00707-9 · Cited by 326
Mortier, E., Woo, T., Advincula, R., Gozalo, S., & Ma, A. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071913 · Cited by 316
Self-citationInsights into Cytokine–Receptor Interactions from Cytokine Engineering
Spangler, J. B., Moraga, I., Mendoza, J. L., & Garcia, K. C. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120211 · Cited by 304
Natural killer cell–directed therapies: moving from unexpected results to successful strategies
Terme, M., Ullrich, E., Delahaye, N. F., Chaput, N., & Zitvogel, L. (2008) · Nature Immunology · doi:10.1038/ni1580 · Cited by 289
Zhang, M., Liu, C., Tu, J., Tang, M., Ashrafizadeh, M., Nabavi, N., Sethi, G., Zhao, P., & Liu, S. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02305-x · Cited by 259
Malamut, G., El Machhour, R., Montcuquet, N., Martin-Lannerée, S., Dusanter-Fourt, I., Verkarre, V., Mention, J.-J., Rahmi, G., Kiyono, H., Butz, E. A., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41344 · Cited by 256
IL-15 signaling in NK cell cancer immunotherapy
Rautela, J., & Huntington, N. D. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.10.004 · Cited by 125
Sène, D., Levasseur, F., Abel, M., Lambert, M., Camous, X., Hernandez, C., Pène, V., Rosenberg, A. R., Jouvin-Marche, E., Marche, P. N., et al. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1001184 · Cited by 113
Interleukin-15 as a myokine: Mechanistic insight into its effect on skeletal muscle metabolism
Nadeau, L., & Aguer, C. (2019) · Applied Physiology Nutrition and Metabolism · doi:10.1139/apnm-2018-0022 · Cited by 83
Metadata
- Authors
- Mortier, E., Quéméner, A., Vusio, P., Lorenzen, I., Boublik, Y., Grötzinger, J., Plet, A., & Jacques, Y.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2006-01
- Volume
- 281
- Issue
- 3
- Pages
- 1612-1619
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W1570245632
- Cited by
- 308
- References
- 37
- FWCI
- 4.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.